Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

  • STATUS
    Recruiting
  • End date
    Feb 28, 2023
  • participants needed
    32
  • sponsor
    Virginia Commonwealth University
Updated on 4 August 2021
platelet count
paclitaxel
renal function
cancer
breast surgery
hysterectomy
cyclophosphamide
decitabine
estrogen
serum pregnancy test
breast cancer
oophorectomy
progesterone
doxorubicin
probe
metastasis
neutrophil count
carboplatin
liver metastasis
advanced breast cancer
pembrolizumab
HER2
chemotherapy regimen
follicle stimulating hormone
estradiol
adenocarcinoma
progesterone receptor
estrogen receptor
breast adenocarcinoma
adenocarcinoma of the breast
core needle biopsy

Summary

This study is a 2-cohort, open-label, multicenter, phase 2 study of a short course of immunotherapy consisting of sequential decitabine followed by pembrolizumab administered prior to a standard neoadjuvant chemotherapy regimen for patients with locally advanced HER2-negative breast cancer. The primary efficacy objective is to determine if the immunotherapy increases the presence and percentage of tumor and/or stromal area of infiltrating lymphocytes prior to initiation of standard neoadjuvant chemotherapy. Efficacy will be evaluated in 2 cohorts based on hormone receptor status.

Description

Both cohorts will receive the identical doses and treatment schedules of decitabine and pembrolizumab followed by a standard neoadjuvant chemotherapy regimen. Both cohorts will receive 4 cycles of dose-dense AC followed by 12 doses of weekly paclitaxel. Paclitaxel will be combined with carboplatin for Cohort A (TNBC). The primary safety objective will be to evaluate the safety and toxicity of sequential decitabine plus pembrolizumab followed by dose-dense AC, weekly paclitaxel (or paclitaxel plus carboplatin) administered as neoadjuvant therapy. If the breast tumor is resectable following completion of all protocol therapy, breast-conserving surgery or mastectomy and axillary surgical staging (either sentinel node biopsy and/or axillary dissection) will be performed.

Details
Condition Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Invasive Breast Carcinoma, Estrogen Receptor Positive Breast Cancer, Invasive Breast Cancer, Adenocarcinoma of the Breast, Breast Adenocarcinoma, ER+ Breast Cancer, Progesterone Receptor Positive Tumor, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Triple-negative Breast Carcinoma, Triple Negative Breast Carcinoma, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, estrogen receptor-positive breast cancer, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor- Negative Breast Cancer, HER2/Neu Negative, HER2/Neu Negative
Treatment cyclophosphamide, carboplatin, Paclitaxel, Pembrolizumab, doxorubicin, Decitabine
Clinical Study IdentifierNCT02957968
SponsorVirginia Commonwealth University
Last Modified on4 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Invasive adenocarcinoma of the breast diagnosed by core needle biopsy
Breast cancer determined to be HER2-negative per current American Society of Clinical Oncologists/College of American Pathologists (ASCO/CAP) HER2 Guidelines (If IHC was performed, IHC 0 or 1+; if fluorescence in situ hybridization [FISH] or other in situ hybridization test, dual probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number < 4.0 signals/cell)
Breast cancer determined to be hormone receptor-positive or hormone receptor-negative defined as follows
Hormone receptor-positive: 10% staining by IHC for either estrogen receptor (ER) or progesterone receptor (PgR)
Hormone receptor-negative: < 10% staining by IHC for both ER and PgR
Locally advanced breast cancer defined as any of the following per American Joint Committee on Cancer (AJCC) Staging Criteria
T2 based on tumor measurements by physical examination or imaging and with clinically positive regional lymph nodes (cN1 or cN2), irrespective of hormone receptor status
Hormone receptor-negative breast cancer patients with tumor size of 3-5 cm measured by physical examination or imaging with clinically negative regional lymph nodes (cN0)
Any T3 based on tumor measurements by physical examination or imaging
Any T4 (including inflammatory breast cancer), irrespective of hormone receptor status
Ipsilateral axillary lymph nodes must be evaluated by MRI or ultrasound within 12 weeks prior to study registration to determine clinical nodal status. If imaging is suspicious or abnormal, a FNA or core biopsy of the questionable node(s) on imaging is required. Nodal status should be classified according to the following criteria
Nodal status - negative
Imaging of the axilla is negative; OR
Imaging of the axilla is suspicious or abnormal AND FNA or core biopsy is negative
Nodal status - positive
FNA or core biopsy of node(s) is cytologically or histologically suspicious or positive
Breast imaging performed prior to study registration as follows
Ipsilateral breast - within 12 weeks
Contralateral breast - within 24 weeks
Age 18 years
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate bone marrow function as defined below
Absolute neutrophil count (ANC) 1,500/mm3
Platelet count 100,000/mm3
Hemoglobin 10.0 g/dL
Adequate renal function as defined below
Serum creatinine upper limit of normal (ULN) for the lab or a calculated creatinine clearance 60 mL/min
Adequate hepatic function as defined below
Total bilirubin ULN for the laboratory
Aspartate aminotransferase (AST) 1.5 x ULN for the laboratory
Alanine aminotransferase (ALT) 1.5 x ULN for the laboratory
Alkaline phosphatase (ALP) 2.5 x ULN for the laboratory Note: If ALP is > 1.5 x ULN, imaging to rule out bone and liver metastasis is required
LVEF assessment (ie, 2-D echocardiogram or MUGA scan) performed within 12 weeks prior to study registration indicates an LVEF 50% regardless of the cardiac imaging facility's lower limit of normal
Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test within 72 hours prior to initiating study treatment
Note: Postmenopausal is defined as any of the following
Age 60 years
Age < 60 years and amenorrheic for at least 1 year with follicle-stimulating hormone (FSH) and plasma estradiol levels in the postmenopausal range
Bilateral oophorectomy
A female patient who is a woman of child-bearing potential (WCBP) and a male patient with a partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of immunotherapy and neoadjuvant chemotherapy and until after completion of breast surgery or, for patients who do not receive neoadjuvant chemotherapy, for a minimum of 6 months following the last dose of pembrolizumab or decitabine
Ability to understand and willingness to sign the consent form

Exclusion Criteria

Breast cancer treatment for the currently diagnosed breast cancer including radiation therapy, chemotherapy, targeted therapy, or endocrine therapy prior to study registration
Administration of a live vaccine within 30 days prior to initiating study treatment Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are permitted; however, intranasal influenza vaccines (eg, Flu-Mist) are live attenuated vaccines, and are not allowed
Administration of a monoclonal antibody within 4 weeks prior to initiating study treatment or has not recovered (ie, grade 1 or at baseline) from AEs due to a monoclonal antibody administered more than 4 weeks earlier
Administration of any investigational agent within 4 weeks prior to initiating study treatment
Evidence of metastatic disease that is extensive enough to preclude consideration of subsequent definitive surgery for the primary tumor
History of ipsilateral invasive breast cancer or ipsilateral ductal carcinoma in situ (DCIS) Note: Patients with history of ipsilateral lobular carcinoma in situ (LCIS) are eligible
History of solid organ or allogeneic stem cell transplant
Previous therapy for any malignancy with an anthracycline or taxane for Cohorts A and B and carboplatin for Cohort A
Cardiac disease that would preclude administration of the drugs included in the study treatment regimen including, but not limited to
Angina pectoris that requires the current use of anti-anginal medication
Ventricular arrhythmias except for benign premature ventricular contractions
Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication
Conduction abnormality requiring a pacemaker
Valvular disease with documented compromise in cardiac function; and symptomatic pericarditis
Nervous system disorder (ie, paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) grade 2, per CTCAE v5.0
Administration of or condition requiring administration of systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating study treatment Exception: Patients with conditions that can be managed with steroids equivalent to or less than an oral prednisone dose of 10 mg daily would not be excluded from the study
Previous therapy for this cancer with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent, or any other immunomodulatory agent
Known or presumed hypersensitivity to decitabine or pembrolizumab (or any of their excipients)
Diagnosed immunodeficiency, eg, human immunodeficiency virus (HIV)
Active autoimmune disease requiring systemic treatment within the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) or a documented history of clinically severe autoimmune disease or a syndrome that requires systemic steroids or immunosuppressive agents Note: Patients with the conditions or medical history listed below are NOT excluded from this study
Vitiligo
Resolved childhood asthma/atopy
Requirement for intermittent use of bronchodilators or local steroid injections or topical steroids
Hypothyroidism stable on hormone replacement
Sjogren's Syndrome
Known history or evidence of interstitial lung disease or active, non-infectious pneumonitis
Known history of active bacillus tuberculosis (TB)
Active infection requiring systemic therapy
Known active Hepatitis B or C
Pregnancy or breastfeeding
Diagnosis or treatment for another malignancy within 5 years prior to study registration, with the following exceptions: complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, any in situ malignancy, and low-risk prostate cancer after curative therapy
Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note